SCP
TEVA icon

Shorepoint Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Shorepoint Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-49,215
Closed -$772K – 88
2019
Q1 		$772K Buy
+49,215
New +$868K 0.44% 64

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shorepoint Capital Partners's TEVA Position: Q2 2019 in Review

Shorepoint Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 49,215 shares — an estimated $772K sold.

Shorepoint Capital Partners first reported a position in TEVA in Q1 2019 and held it in 1 quarter. The position peaked at $772K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Shorepoint Capital Partners reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Shorepoint Capital Partners sold 49,215 Teva Pharmaceuticals shares in Q2 2019, an estimated $772K.
  • Shorepoint Capital Partners first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Shorepoint Capital Partners's Teva Pharmaceuticals position peaked at $772K in Q1 2019.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Shorepoint Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.